SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Prelude Therapeutics Incorporated (PRLD) has a negative trailing P/E of -2.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 48.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -41.16%, forward earnings yield 2.05%. PEG 0.48 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (96/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.48); analyst target implies upside (+42%).
- Forward P/E 48.9 — analysts expect a return to profitability with estimated EPS of $0.09 for FY2028.
- PEG Ratio 0.48 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -41.16% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 2.05% as earnings recover.
- Analyst consensus target $6.25 (+42% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 55/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
96/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PRLD
Valuation Multiples
P/E (TTM)-2.4
Forward P/E48.9
PEG Ratio0.48
Forward PEG0.48
P/B Ratio3.52
P/S Ratio17.63
EV/EBITDA-1.9
Per Share Data
EPS (TTM)$-1.58
Forward EPS (Est.)$0.09
Book Value / Share$1.09
Revenue / Share$0.19
FCF / Share$-0.90
Yields & Fair Value
Earnings Yield-41.16%
Forward Earnings Yield2.05%
Dividend Yield0.00%
Analyst Target$6.25 (+42%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2018 |
-2.8 |
0.00 |
-1.82 |
0.00 |
- |
| 2019 |
-30.8 |
0.34 |
-17.18 |
0.00 |
- |
| 2020 |
-54.9 |
-1.04 |
14.74 |
0.00 |
- |
| 2021 |
-5.3 |
-0.07 |
2.07 |
0.00 |
- |
| 2022 |
-2.5 |
0.96 |
1.46 |
0.00 |
- |
| 2023 |
-2.1 |
0.19 |
1.09 |
0.00 |
- |
| 2024 |
-0.8 |
0.04 |
0.73 |
13.75 |
- |
| 2025 |
-2.2 |
0.10 |
3.25 |
18.38 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.46 |
$0.00 |
$-14.68M |
- |
| 2019 |
$-0.85 |
$0.00 |
$-27.57M |
- |
| 2020 |
$-1.30 |
$0.00 |
$-56.93M |
- |
| 2021 |
$-2.33 |
$0.00 |
$-110.78M |
- |
| 2022 |
$-2.27 |
$0.00 |
$-107.34M |
- |
| 2023 |
$-2.02 |
$0.00 |
$-121.83M |
- |
| 2024 |
$-1.68 |
$7M |
$-127.17M |
-1816.8% |
| 2025 |
$-1.29 |
$12.14M |
$-99.5M |
-819.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.70 |
$-0.70 – $-0.70 |
$50M |
$50M – $50M |
1 |
| 2027 |
$-0.32 |
$-0.32 – $-0.32 |
$100M |
$100M – $100M |
1 |
| 2028 |
$0.09 |
$0.09 – $0.09 |
$200M |
$200M – $200M |
1 |
| 2029 |
$-0.03 |
$-0.03 – $-0.03 |
$100M |
$100M – $100M |
1 |
| 2030 |
$0.37 |
$0.37 – $0.37 |
$100M |
$100M – $100M |
1 |
